alpha Adaptin (AP2A2) Goat Polyclonal Antibody

CAT#: TA319408

Goat polyclonal anti-AP2A antibody



Need it in bulk or conjugated?
Get a free quote

CNY 8,025.00


货期*
5周

规格
    • 100 ug

Product images

经常一起买 (2)
Transient overexpression lysate of adaptor-related protein complex 2, alpha 2 subunit (AP2A2)
    • 100 ug

CNY 3,080.00


beta Actin Mouse Monoclonal Antibody, Clone OTI1, Loading Control
    • 30 ul

CNY 300.00
CNY 1,430.00

Specifications

Product Data
Applications WB
Recommend Dilution ELISA: 1:5,000 - 1:20,000, WB: 1:500 - 1:2,000, IP: 1:100
Reactivity Human, Chimpanzee, Mouse, Rat, Chicken, Dog, Orang-Utan
Host Goat
Clonality Polyclonal
Immunogen This affinity purified antibody was prepared from whole goat serum produced by repeated immunizations with a synthetic peptide corresponding aa 3-14 of Human AP2A1 and AP2A2 proteins.
Formulation 0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2
Concentration lot specific
Conjugation Unconjugated
Storage Condition Store at -20°C as received.
Gene Name adaptor related protein complex 2 alpha 2 subunit
Synonyms ADTAB; CLAPA2; HIP-9; HIP9; HYPJ
Note The AP2A1 and AP2A2 represent the AP2 alpha proteins that are found in the AP2 complex in clathrin-coated vesicles. AP2A is also known as Alpha-adaptin A, Adaptor protein complex AP-2 alpha-1 subunit, Clathrin assembly protein complex 2 alpha-A large chain, 100 kDa coated vesicle protein A and Plasma membrane adaptor HA2/AP2 adaptin alpha A subunit. The AP2 complex is a heterotetramer consisting of two large adaptins (alpha or beta), a medium adaptin (mu), and a small adaptin (sigma). The complex is part of the protein coat on the cytoplasmic face of coated vesicles, which link clathrin to receptors in vesicles.
Reference Data
Protein Pathways Endocytosis, Huntington's disease
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.
Customer Reviews 
Loading...